Dermatology Advisor19m
Tralokinumab Improves Severe Atopic Dermatitis Clinical Scores Long-Term
Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...
ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN Label
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)ANI plans to begin marketing ILU ...
Medpage Today on MSN22h
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor
ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Healio18h
Twice-yearly depemokimab for asthma tolerated well as exacerbation rates fall
Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...